Reimbursed Care Access in British Indian Ocean Territory

Currently classified as a strictly controlled substance under UK-style scheduling applied in BIOT governance, with no authorised medical use outside approved clinical research. Clinical or research access would require a Home Office / controlled‑drugs licence equivalent and any import, possession or supply would need authorisation by the BIOT Administration (or the UK Home Office / MHRA processes where BIOT law defers to English law). # #.

Currently classified as a strictly controlled substance under national drug scheduling laws consistent with UK classifications, with no authorised medical use in BIOT outside approved clinical research. Any lawful medical or research use would require the appropriate controlled‑drugs research licence and regulatory permissions. # #.

Esketamine (intranasal esketamine formulations such as Spravato) is not independently governed by specific BIOT medicines approvals; because BIOT law either follows local BIOT ordinances or, where silent, the law of England, any introduction of Esketamine into clinical use in BIOT would require compliance with UK medicines and controlled‑drugs regimes (MHRA / Home Office) and local BIOT administrative authorisation for import/use. Clinical availability therefore depends on obtaining the relevant licences and supply agreements (for example via UK military/defence medical channels or an MHRA-authorised import), not on routine local reimbursement. The territory does not operate a civilian NHS‑style reimbursement system locally; healthcare on the islands is provided through military/contracted services, so private/administrative procurement channels would be used for any authorised medical supply. # #.

Ketamine is an established medicinal anaesthetic/analgesic that is used in clinical settings and is controlled under UK controlled‑drugs legislation; within BIOT clinical practice (notably on Diego Garcia and in any authorised medical facilities), ketamine may be supplied and administered for licensed medical indications (e.g., anaesthesia) under the territory’s health services and in accordance with controlled‑drugs rules. The BIOT Administration delegates much regulatory practice to UK frameworks where local law is silent, and the UK Controlled Drugs regime lists ketamine as a controlled drug requiring appropriate professional supply and record‑keeping. Operationally this means ketamine is available for standard medical/anaesthetic use in authorised facilities (e.g., military/defence medical services) but there is no public civilian reimbursement framework in BIOT akin to a national health service for civilian psychedelic psychiatric programs. # #.

Regulatory and practical notes: because BIOT has no permanent civilian population and healthcare is provided by or through military/contracted providers, any off‑label psychiatric use of ketamine (for example, infusion for treatment‑resistant depression) would require local clinical governance approval, appropriate controlled‑drugs handling and likely an import/supply arrangement authorised by BIOT administration and the applicable UK authorities. There is no published BIOT civilian reimbursement policy for ketamine as a psychiatric treatment; coverage is therefore a matter of the contracting/operational medical provider (e.g., defence health services) rather than a civilian public insurance scheme. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any lawful access would require research licensing and Home Office/MHRA oversight (or BIOT administrative permissions where applicable). # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any access for research would be subject to Home Office / MHRA licensing and BIOT administrative authorisation as required. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any permitted research would require appropriate licensing and regulatory oversight. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws (its active components include DMT and related tryptamines), with no authorized medical use outside of approved clinical research. Importation or sacramental use would be subject to prohibition or strict licensing, consistent with UK controlled‑drugs policy as applied by BIOT authorities. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws (note: extracts/isolates are controlled; certain cacti as plants may be treated differently in law), with no authorized medical use outside of approved clinical research. Any lawful medical or research handling requires licensing. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws (substituted phenethylamine psychedelics are covered under UK scheduling), with no authorized medical use outside of approved clinical research. Possession, supply or import without appropriate licence is prohibited. # #.